Notes
Also see Reactions 1746 p4; 803382124
Reference
European Medicines Agency. Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs. Internet Document : [4 pages], 17 May 2019. Available from: URL: https://www.ema.europa.eu/en/news/restrictions-use-xeljanz-while-ema-reviews-risk-blood-clots-lungs
Rights and permissions
About this article
Cite this article
Tofacitinib restrictions in place while EU review underway. Reactions Weekly 1755, 7 (2019). https://doi.org/10.1007/s40278-019-62561-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-62561-7